18F-FDG PET/CT在脐尿管腺癌分期与治疗决策中的临床价值
该单中心回顾性研究纳入2001至2019年Memorial Sloan Kettering的21例脐尿管腺癌患者,评估18F-FDG PET/CT对分期与治疗管理的影响。PET/CT在8例(38%)中检出既往未发现的转移灶,使3例(14%)分期上调、4例(19%)治疗方案改变。结论认为PET/CT可通过发现解剖影像未识别的转移改变分期与患者管理。
要点
- 18F-FDG PET/CT在38%(8/21)脐尿管腺癌患者中检出解剖影像未发现的转移。
- PET/CT导致14%(3/21)患者分期上调、19%(4/21)患者治疗改变。
- 研究支持PET/CT用于脐尿管腺癌分期与治疗决策。
核心结论
- 18F-FDG PET/CT对脐尿管腺癌具有临床价值,可发现解剖影像未识别的转移,进而改变分期与患者管理。
研究设计与样本
- 单中心回顾性分析2001至2019年Memorial Sloan Kettering的21例脐尿管腺癌患者。
- 比较18F-FDG PET/CT前后的Mayo分期,并记录原发灶与转移灶检出率及管理变化。
主要发现
- PET/CT前Mayo分期为I/II期8例、III期3例、IV期10例。
- PET/CT在8例(38%)中检出既往未发现的转移灶。
- PET/CT导致3例(14%)分期上调、4例(19%)治疗改变。
临床怎么用
- 对脐尿管腺癌患者可考虑行18F-FDG PET/CT以补充解剖影像分期,辅助治疗决策。
局限性
- 回顾性单中心设计,样本量仅21例,结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our objective was to evaluate the impact of 18F-FDG PET CT on the management of urachal adenocarcinoma (UrC-ADC). Methods: A retrospective analysis of patients with UrC-ADC from 2001 to 2019 at Memorial Sloan Kettering was performed. Mayo stage before 18F-FDG PET/CT, rate of detection of the primary malignancy and metastases on 18F-FDG PET/CT, Mayo stage after 18F-FDG PET/CT, and change in patient management were determined. Results: Of 21 patients with UrC-ADC before 18F-FDG PET/CT, Mayo staging was I/II in 8, III in 3, and IV in 10. 18F-FDG PET/CT detected previously unidentified metastases in 8 (38%) of 21 patients, resulting in upstaging of disease in 3 (14%) patients and a change in treatment in 4 (19%) patients. Conclusion:18F-FDG PET/CT has clinical utility in patients with UrC-ADC by identifying metastatic disease not appreciated on anatomic imaging, leading to changes in staging and patient management.
引用
- Das JP, Vargas HA, Ghafoor S, et al. Clinical Utility of 18F-FDG PET/CT for Staging and Treatment Planning in Urachal Adenocarcinoma. J Nucl Med. 2020. PMID: 32948680. doi:10.2967/jnumed.120.251561
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。